quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 28, 2026

Have Salesforce shares hit bottom? BNP Paribas eyes catalysts to turn stock around

View original at seekingalpha.com
Have Salesforce shares hit bottom?…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • At 4Q results, Salesforce announced a $50bn repurchase authorization, with the first $20bn completed by 3/15, the next $5bn completed by the end of FY27e, and the final $25bn yet to be scheduled

    60% confidence
  • Buybacks are clearly not enough to trigger new investor interest or confidence, but next week's event highlighting Slackbot may serve as a near-term catalyst as it is likely to be another step in demonstrating real-world customer adoption of Salesforce's AI products

    60% confidence
  • Total FY27 buyback estimate increases to ~$25bn from ~$16bn previously, driving an 8% reduction in diluted share count for FY27 versus prior estimate

    60% confidence
  • Salesforce stock might have finally reached its low point, and multiple near-term catalysts could help

    60% confidence

Data points we hold from this source

Salesforce · share buyback completed20 USD
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Have Salesforce shares hit bottom? BNP Paribas eyes catalysts to turn stock around — Source | Via News | pt.VIA.NEWS